Skip to Content

HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

In the context of the Checkmate 214 trial, demonstrating health-related quality of life (HRQoL) benefits in patients with renal cell carcinoma (RCC) receiving immune checkpoint inhibitors (ICIs) in the first-line treatment, Professor David Cella is now ready to disclose the prognostic ability of these HRQoL data.

David Cella, Dr

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top